Cost-Effectiveness Analysis of Bevacizumab, Fotemustine and Extended-Dose Temozolomide in Patients with Recurrent Glioblastoma in Spain
Nov 1, 2014, 00:00
10.1016/j.jval.2014.08.2298
https://www.valueinhealthjournal.com/article/S1098-3015(14)04228-4/fulltext
Title :
Cost-Effectiveness Analysis of Bevacizumab, Fotemustine and Extended-Dose Temozolomide in Patients with Recurrent Glioblastoma in Spain
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)04228-4&doi=10.1016/j.jval.2014.08.2298
First page :
A638
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
1753